Latest Information Update: 21 Feb 2006
At a glance
- Originator Innovata
- Mechanism of Action Opioid mu receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 21 Feb 2006 No development reported - Phase-II for Pain in United Kingdom (Inhalation)
- 14 Jul 2005 Innovata Biomed has merged with ML Laboratories to form Innovata
- 28 Feb 2003 Phase-II clinical trials in Pain in United Kingdom (Inhalation)